They also infused T-cell depleted grafts (with CD3 or CD3/CD19 depletion) from MMFD after fludarabine/cyclophosphamide conditioning—with the addition of TBI in three patients—and reported a 2-year OS of 88% with ≥ grade III acute GVHD of 25%, no severe chronic GVHD, and a TRM of 10% [34]. The gene discussed is CD19; the disease is acute graft versus host disease.